Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

IOVA

Rang in Aktien #2786
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Aktienkurs
$14.87
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$6.74B
Veränderung (1 Tag)
4.64%
Veränderung (1 Jahr)
555.03%
Land
US
Handel Iovance Biotherapeutics, Inc. (IOVA)

Kategorie

Healthcare
Aktien-Split-Historie für Iovance Biotherapeutics, Inc. (IOVA)
Die Aktie Iovance Biotherapeutics, Inc. (Symbol: IOVA) durchlief insgesamt 2 Aktiensplits.
Der letzte Aktiensplit fand am Sep 26, 2013 statt.
Eine IOVA-Aktie, die vor dem May 26, 2010 gekauft wurde, entspricht heute 0.23999 IOVA-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
2013-09-26 1:100 x0.01 x0.23999
2010-05-26 23999:1000 x23.999 x23.999
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL